Loading organizations...
Key people at UF Innovate Ventures.
UF Innovate Ventures commercializes University of Florida research by fostering the growth of technology-based startup companies. It streamlines the transition of UF inventions from academic laboratories to the marketplace, providing essential support and strategic investment opportunities to accelerate entrepreneurial development and cultivate scalable businesses. The initiative focuses on building foundational infrastructure for these nascent ventures.
Operating within the broader UF Innovate framework, Ventures is an integral part of the University of Florida's strategy to cultivate an innovation ecosystem. While specific individual founders for this particular arm are not publicly emphasized, its establishment stems from the university's enduring commitment to translating scholarly research into tangible economic and societal benefits, aiming to formalize and bolster support for university-affiliated startups.
The primary beneficiaries of UF Innovate Ventures are university researchers and entrepreneurs seeking to commercialize their scientific and technological discoveries. Its overarching vision is to stimulate economic expansion by transforming academic breakthroughs into successful enterprises, thereby enhancing Florida's innovative capacity and ensuring that pioneering university research yields widespread practical applications.
Key people at UF Innovate Ventures.
UF Innovate Ventures has 2 tracked investments across 2 companies. The latest tracked deal is $51.0M Series A in Kate Therapeutics in June 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 1, 2023 | Kate Therapeutics | $51.0M Series A | Versant Ventures, Westlake Village BioPartners | 5AM Ventures, RA Capital, Osage University Partners |
| Mar 1, 2021 | StrideBio | $82.0M Series B | Northpond Ventures, Novo Ventures | Advanced Technology Ventures, RA Capital, Venrock, Alexandria Venture Investments, Caas Capital Management, Hatteras Venture Partners, Octagon Capital, Pontifax, Sarepta Therapeutics, Takeda Ventures, UCB Ventures |